Objective: To identify and compare population-based genetic databases, or ‘genebanks’, that have been proposed in eight international locations between 1998 and 2002. A genebank can be defined as a stored collection of genetic samples in the form of blood or tissue, that can be linked with medical and genealogical or lifestyle information from a specific population, gathered using a process of generalized consent. Methods: Genebanks were identified by searching Medline and internet search engines with key words such as ‘genetic database’ and ‘biobank’ and by reviewing literature on previously identified databases such as the deCode project. Collection of genebank characteristics was by an electronic and literature search, augmented by correspondence with informed individuals. The proposed genebanks are located in Iceland, the United Kingdom, Estonia, Latvia, Sweden, Singapore, the Kingdom of Tonga, and Quebec, Canada. Comparisons of the genebanks were based on the following criteria: genebank location and description of purpose, role of government, commercial involvement, consent and confidentiality procedures, opposition to the genebank, and current progress. Results: All of the groups proposing the genebanks plan to search for susceptibility genes for complex diseases while attempting to improve public health and medical care in the region and, in some cases, stimulating the local economy through expansion of the biotechnology sector. While all of the identified plans share these purposes, they differ in many aspects, including funding, subject participation, and organization. The balance of government and commercial involvement in the development of each project varies. Genetic samples and health information will be collected from participants and coded in all of the genebanks, but consent procedures range from presumed consent of the entire eligible population to recruitment of volunteers with informed consent. Issues regarding confidentiality and consent have resulted in opposition to some of the more publicized projects. None of the proposed databases are currently operational and at least one project was terminated due to opposition. Conclusions: Ambitious genebank projects have been proposed in numerous countries and provinces. The characteristics of the projects vary, but all intend to map genes for common diseases and hope to improve the health of the populations involved. The impact of these projects on understanding genetic susceptibility to disease will be increasingly apparent if the projects become operational. The ethical, legal, and social implications of the projects should be carefully considered during their development.

Keywords:
Population genetics, Genebank, Genetic database, Biological sample
1.
Lander ES, Linton LM, Birren B, et al: Initial sequencing and analysis of the human genome. Nature 2001;409:860–921.
2.
Venter JC, Adams MD, Myers EW, et al: The sequence of the human genome. Science 2001;291:1304–1351.
3.
Collins FS, Guttmacher AE: Genetics moves into the medical mainstream. JAMA 2001;286:2322–2324.
4.
Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W: Potential role of pharmacogenomics in reducing adverse drug reactions: A systematic review. JAMA 2001;286:2270–2279.
5.
Beskow LM, Khoury MJ, Baker TG, Thrasher JF: The integration of genomics into public health research, policy and practice in the United States. Community Genet 2001;4:2–11.
6.
Althingi: 1998. Act on a Health Sector Database No 139/1998. Available from: http://government.is/interpro/htr/htr.nsf/pages/gagngr-log-ensk. Accessed 12 Apr 2002.
7.
Althingi: 2000. Operating License, State Reg No 691295–3549. Available from: http://government.is/interpro/htr/htr.nsf/pages/operat-lic. Accessed 12 Apr 2002.
8.
Association for Ethics in Science and Medicine in Iceland. Available from: www.mannvernd. is. Accessed 17 Mar 2002.
9.
Lewis R: Founder populations fuel gene discovery. Scientist 2001;15:8.
10.
Zak NB, Shifman A, Darvasi A: Population-based gene discovery in the post genomic era. DDT 2001;6:1111–1115.
11.
Abbott A: Manhattan vs. Reykjavik. Nature 2000;406:340–342.
12.
Arnason E, Sigurgislason H, Benedikz E: Genetic homogeneity of Icelanders: Fact or fiction? Nat Genet 2000;25:373–374.
13.
Burton B: Proposed genetic database on Tongans opposed. BMJ 2002;324:443.
14.
DeCode Genetics: Available from: www.decode.com. Accessed 17 Mar 2002.
15.
Newfound Genomics: Available from: www.newfound-genomics.com. Accessed 5 Apr 2002.
16.
Autogen Limited: Available from: www.autogenlimited.com.au. Accessed 12 Apr 2002.
17.
Estonian Genome Foundation: Available from: www.genomics.ee. Accessed 17 Mar 2002.
18.
EGeen: Available from: www.genomics.ee/genome/egeen.html. Accessed 6 Nov 2001.
19.
Liberty: Available from: www.Liberty-human-rights.org.uk. Accessed 17 Mar 2002.
20.
Gulcher J, Stefansson K: Ethics of population genomics research. Nature 1999;400:307–308.
21.
Anderson B, Zoega T: Letter to the editor: Icelandic genetics. Nat Biotechnol 1999;17:517.
22.
Frank L: Biotechnology in the Baltic. Nat Biotechnol 2001;19:513–515.
23.
Gulcher J, Stefansson K: An Icelandic saga on a centralized healthcare database and democratic decision making. Nat Biotechnol 1999;17:620.
24.
Hagmann M: UK plans major medical DNA database. Science 2000;287:1184.
25.
Gulcher J, Stefansson K: The Icelandic Healthcare Database and informed consent. N Engl J Med 2000;342:1827–1830.
26.
Annas G: Rules for research on human genetic variation – lessons from Iceland. N Engl J Med 2000;342:1830–1833.
27.
Icelandic Minister of Health and Social Security: 2000 Agreement between the Minister for Health and Social Security and Íslensk erfðagreining ehf. relating to the issue of an operating license for the creation and operation of a Health Sector Database. Available from: http://government.is/interpro/htr/htr.nsf/Files/Aggreement/$file/AGREEMENT-english.pdf. Accessed 17 Oct 2002.
28.
Greely H: Iceland’s plan for genomics research: Facts and implications. Jurimetrics 2000;40:153–191.
29.
Althingi: 2000. Act on Biobanks no. 110/2000. Available from: http://government.is/interpro/htr/htr.nsf/pages/Act-biobanks. Accessed 12 Apr 2002.
30.
The Althingi. 2000. Government Regulation on a Health Sector Database No 32/2000 Available from: http://government.is/interpro/htr/htr.nsf/pages/Govreg32-2000. Accessed 12 Apr 2002.
31.
Joint Statement of the Icelandic Medical Association and deCode Genetics on the Health Sector Database: 2001 Available from: www.decode.com. Accessed 5 Nov 2001.
32.
Wade N: A genomic treasure hunt may be striking gold. NY Times 18 June 2002;Sect F: 1 (col5).
33.
Anonymous: Report of the UK population biomedical collection protocol development workshop. Available from: http://www.mrc.ac.uk/pdf-biobank_protocol.pdf. Accessed 17 Mar 2002.
34.
People Science and Policy Ltd.: 2002 Biobank UK: A question of trust: A consultation exploring and addressing questions of public trust. Available from: http://www.ukbiobank.ac.uk/documents/consultation.pdf. Accessed 5 Oct 2002.
35.
Anonymous: Draft Protocol for Biobank UK: A study of genes, environment and health. Available from: http://www.ukbiobank.ac.uk/documents/draft_protocol.pdf. Accessed 17 Mar 2002.
36.
Kmietowicz Z: UK gene bank a step closer. BioMed Central Online 2001; Available from www.biomedcentral.com/news/20010221/05.
37.
Genewatch UK: Available from www.genewatch.org/. Accessed 17 Mar 2002.
38.
Estonian Genome Foundation: Estonian Genome Project concluded financing agreements. Press Release 2 Jan 2002. Available from: http://www.geenivaramu.ee/index.php?lang=eng&show=uudised&sel=&offset=10. Accessed 2 Mar 2002.
39.
Riigikogu: Human Genes Research Act. 2000. Available from: http://www.geenivaramu.ee/mp3/HumanGenesResearchAct.doc. Accessed 17 Mar 2002.
40.
Anonymous: International Special Reports. Mapping Estonia: Estonia takes on an ambitious project to outline the country’s genome. Available from: www.internationalspecialreports.com/europe/01/estonia/education/index.html. Accessed 16 Nov 2001.
41.
Genome Database of the Latvian Population: Project Annotation 2002.
42.
Abbott A: Hopes of biotech interest spur Latvian population genetics. Nature 2001;412:468.
43.
Abbott A: Sweden sets ethical standards for use of genetic ‘biobanks’. Nature 1999;400:3.
44.
Swedish Medical Research Council: Research ethics guidelines for using biobanks, especially projects involving genome research. Available from: http://www.forsketik.lu.se/biobank-e.html. Accessed 4 Mar 2002.
45.
Nilsson A, Rose J: Sweden takes steps to protect tissue banks. Science 1999;286:894.
46.
Wingerson L: Singapore thinks big: Genomics and beyond. HMS Beagle 2001;108 Available from: www.bmn.com.
47.
Cyranoski D: Singapore to create nationwide disease database. Nature 2000;407:935.
48.
Lee K: Singapore focuses its life strategy on humans. Curr Biol 2001;11:R3.
49.
Bouchard G: CARTaGENE project holds exceptional promise for Quebec. Le Soleil, Jan 23, 2002. Available from: www.quebecnews.com.
50.
Pare I: Quebec has developed a unique knowledge base. Le Devoir Jun 17, 2000, pp 2–3.
51.
Hollon T: Gene pool expeditions – Estonians or subjects of the crown of Tonga: Whose gene pool hides gold? Scientist 2001;15:1.
52.
UmanGenomics: Available from: www.umangenomics.com. Accessed 17 Mar 2002.
53.
Anonymous: n.d. Biobank UK: A study of genes, environment and health. Available from: www.wellcome.ac.uk/en/1/biovenpop.html. Accessed 12 Apr 2002.
54.
National Bioethics Advisory Committee: 1999 Research involving human biological materials: Ethical issues and policy guidelines.
55.
Frank L: Storm brews over gene bank of Estonian population. Science 1999;286:1262–1263.
56.
Vogel G: UK’s mass appeal for disease insights. Science 2002;296:824.
57.
Hakonarson H, Bjornsdottir U, Halapi E et al: A major susceptibility gene for asthma maps to chromosome 14q24. Am J Hum Genet 2002;71:483–491.
58.
Stefansson H, Sigurdsson E, Steinthorsdottir V, et al: Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 2002;71:877–892.
59.
Schmickle S: Mayo files hold trove of family data. Minneapolis Star Tribune, May 28, 2002.
60.
Marshfield Clinic. Personalized Medicine Research Project. Available from: research.marshfieldclinic.org/pmrc. Accessed 12 Sep 2002.
61.
Caldwell M: The establishment of a national resource for personalized medicine. Gene Technology Forum, Tartu, 2002.
62.
Brown H: It’s all in the genes: The purer the gene pool, the easier to trace disease evolution. 2001. Available from: http://abcnews.go.com/sections/wnt/WorldNewsTonight/wnt010702_sardinia_feature.html.
63.
Fleishman J: Nearly pure bloodlines put village onto genetics map. Philadelphia Inquirer, Apr 8, 2001, A01.
64.
Carroll R: Meet the people of Genetic Park. Guardian, Oct 30, 2000. Available from: http://www.guardian.co.uk/genes/article/0,2763,389969,00.html.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.